Evidence map›Paper›PMID 38851717›Full record

ArticleNPJ Parkinson's disease2024

Predictors of short-term anxiety outcome in subthalamic stimulation for Parkinson's disease.

Anna Sauerbier, Johanna Herberg, Vasilija Stopic, Philipp A Loehrer, Keyoumars Ashkan, Alexandra Rizos, Stefanie T Jost, Jan Niklas Petry-Schmelzer, Alexandra Gronostay, Christian Schneider and 13 more

Abstract read
In one paragraph

Article in NPJ Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Behavioral disorders in Parkinson disease: current view.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Anna SauerbierUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany. anna.sauerbier@uk-koeln.de.
Johanna HerbergUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
Vasilija StopicUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
Philipp A LoehrerDepartment of Neurology, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.ORCID http://orcid.org/0000-0002-5279-2156
Keyoumars AshkanParkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.
Alexandra RizosParkinson Foundation International Centre of Excellence, King's College Hospital, London, UK.
Stefanie T JostUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
Jan Niklas Petry-SchmelzerUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.ORCID http://orcid.org/0000-0003-0749-3840
Alexandra GronostayUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
Christian SchneiderUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.
Veerle Visser-VandewalleUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Stereotactic and Functional Neurosurgery, Cologne, Germany.ORCID http://orcid.org/0000-0002-5274-7929
Julian EvansDepartment of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Greater Manchester, UK.
Christopher NimskyDepartment of Neurosurgery, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.ORCID http://orcid.org/0000-0002-8216-9410
Gereon R FinkUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany.ORCID http://orcid.org/0000-0002-8230-1856
Angelo AntoniniParkinson and Movement Disorders Unit, Department of Neurosciences (DNS), University of Padua, Padova, Italy.ORCID http://orcid.org/0000-0003-1040-2807
Pablo Martinez-MartinCenter for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
Monty SilverdaleDepartment of Neurology and Neurosurgery, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, Greater Manchester, UK.
Daniel WeintraubDepartments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 19104-2676, USA.ORCID http://orcid.org/0000-0003-0633-7168
Anette SchragDepartment of Clinical and Movement Neurosciences, UCL Institute of Neurology, University College London, London, UK.ORCID http://orcid.org/0000-0002-9872-6680
K Ray ChaudhuriInstitute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.ORCID http://orcid.org/0000-0003-2815-0505
Lars TimmermannDepartment of Neurology, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
Haidar S DafsariUniversity of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Neurology, Cologne, Germany. haidar.dafsari@uk-koeln.de.ORCID http://orcid.org/0000-0001-8849-4233
EUROPAR, the German Parkinson Society Non-motor Symptoms Study Group, and the International Parkinson and Movement Disorders Society Non-Motor Parkinson’s Disease Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effects of subthalamic nucleus deep brain stimulation (STN-DBS) on anxiety in Parkinson's disease (PD) are understudied. We identified clinical predictors of STN-DBS effects on anxiety in this study. In this prospective, open-label, multicentre study, we assessed patients with anxiety undergoing STN-DBS for PD preoperatively and at 6-month follow-up postoperatively. We assessed the Hospital Anxiety and Depression Scale (HADS-anxiety and depression subscales), Unified PD Rating Scale-motor examination, Scales for Outcomes in PD-motor (SCOPA-M)-activities of daily living (ADL) and -motor complications, Non-Motor Symptom Scale (NMSS), PDQuestionnaire-8 (PDQ-8), and levodopa-equivalent daily dose. We tested changes at follow-up with Wilcoxon signed-rank test and corrected for multiple comparisons (Bonferroni method). We identified patients with a clinically relevant anxiety improvement of anxiety based on a designated threshold of ½ standard deviation of baseline HADS-anxiety. Moreover, we investigated predictors of HADS-anxiety changes with correlations and linear regressions. We included 50 patients with clinically relevant baseline anxiety (i.e., HADS-anxiety ≥ 8) aged 63.1 years ± 8.3 with 10.4 years ± 4.5 PD duration. HADS-anxiety improved significantly at 6-month follow-up as 80% of our cohort experienced clinically relevant anxiety improvement. In predictor analyses, worse baseline SCOPA-ADL and NMSS-urinary domain were associated with greater HADS-anxiety improvements. HADS-anxiety and PDQ-8 changes correlated moderately. Worse preoperative ADL and urinary symptoms predicted favourable postoperative anxiety outcome, which in turn was directly proportionate to greater QoL improvement. This study highlights the importance of detailed anxiety assessments alongside other non-motor and motor symptoms when advising and monitoring patients undergoing STN-DBS for PD.

Identifiers

PMID38851717
PMCPMC11162430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.